Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down
BIO misses Q4 EPS estimates as margins shrank and shares slid 12%, despite revenue growth and a rebound in Clinical Diagnostics sales.
Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript
Bio-Rad Laboratories (BIO) Q4 Earnings Miss Estimates
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago.
Artisan Mid Cap Value Fund Q4 2025 Performance Discussion And Portfolio Activity
Online travel agency Expedia, our top overall contributor in Q4, drove performance in the consumer discretionary sector. Our top performers in the energy and financials sectors were NOV, a provider of oilfield equipment, technology and expertise, and First Citizens, a North Carolina-based bank. Our largest new purchase was Houston-headquartered Prosperity BancShares, the fifth-largest bank in Texas.
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio Now
BIO benefits from steady Clinical Diagnostics demand and international growth, but macro pressures and currency headwinds could cap near-term upside.
Bio-Rad's Q3 Earnings Miss Estimates, Revenues Surpass, Stock Falls
BIO's Q3 earnings fall short of estimates despite higher revenues, as margin pressure and weak research demand weigh on results.
Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Earnings Call Transcript
Bio-Rad Laboratories, Inc. ( BIO ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Yong Chung - Vice President of Investor Relations Jonathan DiVincenzo - President & COO Roop Lakkaraju - Executive VP & CFO Norman Schwartz - Chairman & CEO Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division Daniel Leonard - UBS Investment Bank, Research Division Brandon Couillard - Wells Fargo Securities, LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Nephron Research LLC Presentation Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.
Bio-Rad Laboratories (BIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants Roop Lakkaraju - Executive VP & CFO Norman Schwartz - Chairman & CEO Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst Good afternoon. Welcome to the Wells Fargo Healthcare Conference.
Is it Apt to Hold Bio-Rad Stock in Your Portfolio Now?
BIO's strong ddPCR growth and solid diagnostics demand support its stock despite market pressures and stiff competition.
Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause
The U.S. Government plans to cut the annual budget allocated to the NIH by 40% in 2026. This decision could have an adverse effect on the operations of Bio-Rad. Bio-Rad projects 0.5% revenue growth for 2025, indicating that it encounters problems in expanding its operations. The four relative valuations conducted in this article reported mixed results. These results suggest that the company trades at fair value.
Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q2 2025 Earnings Conference Call July 31, 2025 5:00 PM ET Company Participants Jonathan P. DiVincenzo - President & COO Norman D.
